Stifel Initiates Coverage On Summit Therapeutics with Buy Rating, Announces Price Target of $45

Benzinga Newsdesk www.benzinga.com Positive 50.9%

Neg 0% Neu 0% Pos 50.9%

Stifel analyst Dara Azar initiates coverage on Summit Therapeutics (NASDAQ:SMMT) with a Buy rating and announces Price Target of $45.